- Q3 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 14, 2024$1.59 (-2.45%)Earnings
- Q2 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 14, 2023$1.45 (+20.83%)Earnings
- Q1 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2023$2 (-0.99%)Earnings
- Immunoprecise Antibodies Ltd To Participate in an Interview Hosted by Market Radius Research TranscriptJul 19, 2023
- Q4 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 07, 2023$2.99 (-1.32%)Earnings
- Immunoprecise Antibodies Ltd at Smallcap Discoveries TranscriptJun 28, 2023
- Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q3 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 16, 2023$3.37 (-10.13%)Earnings
- Q2 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 15, 2022$4.9 (-8.58%)Earnings
- Q1 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2022$4.85 (-9.85%)Earnings
- Q4 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 29, 2022$4.23 (-7.03%)Earnings
- Q2 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 13, 2021$5.06 (-9.96%)Earnings
- Immunoprecise Antibodies Ltd LifeScience Webinar TranscriptApr 28, 2021
Q2 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Good morning, and thank you for standing by. Welcome to ImmunoPrecise Antibodies' second-quarter fiscal year 2023 earnings conference call. Also, on the call with us today are Jennifer Bath, Chief Executive Officer; Brad McConn, Chief Financial Officer; Ilse Rodink, Chief Scientific Officer; and Barry Duplantis, Vice President of Client Relations.
Before we get started, remember, some statements we make today may be considered forward-looking statements for the purposes of applicable United States and Canadian securities laws. IPA cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. IPA undertakes no obligation to update these forward-looking statements, except as required by law.
On today's call, non-GAAP financial measures may be used to help investors and analysts understand IPA's business performance. We refer current and potential investors to the forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)